| Literature DB >> 32816733 |
Stefan H F Hagmann1,2, Kristina M Angelo3, Ralph Huits4, Katherine Plewes5, Gilles Eperon6, Martin P Grobusch7, Anne McCarthy8, Michael Libman9, Eric Caumes10, Daniel T Leung11, Hilmir Asgeirsson12,13, Mogens Jensenius14, Eli Schwartz15,16, Adrian Sánchez-Montalvá17, Paul Kelly18, Prativa Pandey19, Karin Leder20,21, Daniel L Bourque22,23, Yukihiro Yoshimura24, Frank P Mockenhaupt25,26, Perry J J van Genderen27, Silvia Odolini28,29, Patricia Schlagenhauf30, Bradley A Connor31, Davidson H Hamer32,33,34.
Abstract
Enteric fever, caused by Salmonella enterica serovar Typhi (S Typhi) and S. enterica serovar Paratyphi (S Paratyphi), is a common travel-related illness. Limited data are available on the antimicrobial resistance (AMR) patterns of these serovars among travelers. Records of travelers with a culture-confirmed diagnosis seen during or after travel from January 2007 to December 2018 were obtained from GeoSentinel. Traveler demographics and antimicrobial susceptibility data were analyzed. Isolates were classified as nonsusceptible if intermediate or resistant or as susceptible in accordance with the participating site's national guidelines. A total of 889 travelers (S Typhi infections, n = 474; S Paratyphi infections, n = 414; coinfection, n = 1) were included; 114 (13%) were children of <18 years old. Most individuals (41%) traveled to visit friends and relatives (VFRs) and acquired the infection in South Asia (71%). Child travelers with S Typhi infection were most frequently VFRs (77%). The median trip duration was 31 days (interquartile range, 18 to 61 days), and 448 of 691 travelers (65%) had no pretravel consultation. Of 143 S Typhi and 75 S Paratyphi isolates for which there were susceptibility data, nonsusceptibility to antibiotics varied (fluoroquinolones, 65% and 56%, respectively; co-trimoxazole, 13% and 0%; macrolides, 8% and 16%). Two S Typhi isolates (1.5%) from India were nonsusceptible to third-generation cephalosporins. S Typhi fluoroquinolone nonsusceptibility was highest when infection was acquired in South Asia (70 of 90 isolates; 78%) and sub-Saharan Africa (6 of 10 isolates; 60%). Enteric fever is an important travel-associated illness complicated by AMR. Our data contribute to a better understanding of region-specific AMR, helping to inform empirical treatment options. Prevention measures need to focus on high-risk travelers including VFRs and children.Entities:
Keywords: antimicrobial resistance; enteric fever; paratyphoid; travel; typhoid
Year: 2020 PMID: 32816733 PMCID: PMC7577154 DOI: 10.1128/AAC.01084-20
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191